Misonix merges with Bioventus
Clients Misonix, Inc.
Jones Day represented Misonix, Inc. (Nasdaq: MSON) in its acquisition by Bioventus Inc. (Nasdaq: BVS). Misonix is a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes and Bioventus is a global leader in innovations for active healing.
Under the terms of the agreement, Misonix stockholders will receive aggregate consideration that values Misonix at approximately $518 million. In the transaction, Misonix stockholders may elect to receive either (i) 1.6839 shares of Bioventus class A common stock or (ii) $28.00 in cash, without interest, for each share of Misonix common stock they hold, subject to proration The consideration will involve a cash amount payable by Bioventus equal to $10.50 per share of Misonix common stock outstanding shortly prior to the completion of the transaction with the remainder of the consideration payable Bioventus class A common stock. The aggregate stock consideration represents 25% of the combined company on a fully diluted basis. Two members of the Misonix board will join the Bioventus board at the completion of the transaction.